Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Accounts Payables (2024 - 2025)

Allarity Therapeutics' Accounts Payables history spans 2 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 2.39% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, up 2.39%, while the annual FY2025 figure was $4.3 million, 2.39% up from the prior year.
  • Accounts Payables reached $4.3 million in Q4 2025 per ALLR's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.1 million in Q1 2024 to a low of $4.2 million in Q4 2024.